Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory Diseases.
Ilse A Pool, Alise D E de Groot, Ron J Keizer et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the pharmacokinetics of IL-23p19 inhibitors across various immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD). It included 21 studies and found that risankizumab showed similar pharmacokinetic parameters in Crohn's disease and ulcerative colitis, with increased trough levels over consecutive doses. The study highlights the need for more research on IBD-specific pharmacokinetics.
Key findings
- Risankizumab showed similar dose-normalized maximum concentrations in Crohn's disease and ulcerative colitis.
- Patients with Crohn's disease and ulcerative colitis had increased risankizumab trough levels over consecutive dosing intervals.
- Only albumin in ulcerative colitis and body weight in Crohn's disease were relevant covariates for risankizumab pharmacokinetics.
- Limited pharmacokinetic data exists for specific IBD subphenotypes, indicating a need for further research.
Why it matters
Understanding the pharmacokinetics of IL-23p19 inhibitors is crucial for optimizing treatment strategies in immune-mediated inflammatory diseases. This knowledge can help clinicians tailor therapies to individual patient needs, potentially improving treatment efficacy and patient outcomes.